Introduction: Esophageal carcinoma is characterized by a high frequency of lymph node metastasis (LNM). It is difficult to accurately define the radiotherapeutic clinical target volume in patients with thoracic esophageal squamous cell carcinoma (ESCC), because the LNM rate and the included node level varied greatly among previous studies. This study aimed to determine which node level should be included for radiotherapy by analyzing LNM rate in thoracic ESCC patients. Methods: The clinicopathological factors related to LNM were analyzed using the χ 2 test. The sites with LNM rate higher than 15%, an empirical cutoff value, were considered as high-risk areas and were included in clinical target volume of thoracic ESCC patients for radiotherapy. Results: This study included 1893 thoracic ESCC patients treated at Shandong Cancer Hospital, Jinan, China. The rates of LNM in patients with upper thoracic tumors were 14.6% cervical, 29.3% upper mediastinal, 8.5% middle mediastinal, 9.8% lower mediastinal, and 7.3% abdominal, respectively. The rates of LNM in patients with middle thoracic tumors were 4.3%, 5.0%, 32.9%, 2.5%, and 14.9%, respectively. The rates of LNM in patients with lower thoracic tumors were 2%, 2.2% 15.4%, 38.1%, and 27.5%, respectively. Independent prognostic factors for LNM included length of tumor, histologic differentiation, and depth of tumor invasion (p < 0.001). Conclusions: Irradiation of the selective regional lymph node and the correlated lymphatic drainage regions should be performed according to the clinicopathological factors. For the large, deeply invasive longer tumors and poorly differentiated thoracic ESCC, the irradiation field should be enlarged appropriately.
sophageal carcinoma is characterized by a high frequency of lymph node metastasis (LNM), and surgery is the mainstay of treatment for operable esophageal carcinoma. 1 The pattern of LNM is one of the definitive factors influencing both the overall survival rate, and therapeutic decision making of esophageal carcinoma. Tachikawa et al. 2 reported that the metastatic mode of lymph node can reflect the degree of esophageal cancer progression and thus was an important prognostic factor. Ooki et al. 3 showed that LNM density and growth were the most important prognostic factors in esophageal squamous cell carcinoma (ESCC). Therefore, the understanding of risk factors related to LNM is beneficial in identifying patients who are more likely to have lymph nodes involved and in guiding the individualized therapy. However, systemic and local recurrence remains high in advanced esophageal carcinoma even after complete tumor resection and extensive lymphadenectomy, resulting in low 5-year survival rate. 4 In addition, most of the esophageal carcinomas are already in an advanced stage when diagnosed, thus surgery is inappropriate in up to 40% to 60% of patients because of reasons such as unresectable tumor, presence of distant metastases, and high operative risk. 5 These patients are usually treated with radiotherapy. There is consensus that the gross tumor volume consists of the primary tumor and positive lymph nodes. However, there is no general recommendation on the lymph node regions that should be included in the clinical target volume (CTV) for radiotherapy. In this study, the pattern of LNM in ESCC patients treated with three-field or two-field lymphadenectomy was analyzed, and the impact of LNM on the radiotherapeutic CTV delineation in thoracic ESCC was investigated.
PATIENTS AND METHODS

Patients Characteristics
All patients underwent computed tomography or positron emission tomography scans for preoperative staging workup. Cervical ultrasonography was also performed for the detection of cervical lymphadenopathy. The exclusion criteria included preoperative radiotherapy or chemotherapy, invasion to cervical esophagus and cardiac part of the stomach, and distant metastasis. Informed consent was obtained from each patient. This study was approved by the Ethics Committee of our hospital. The demographic information of the patients is shown in Table 1 .
Naming and Numbers of Lymph Node Stations
To accurately describe the incidence and pattern of LNM and the extent of lymphadenectomy, the terminology of the regional lymph nodes of esophageal cancer was defined by the Japanese Society for Esophageal Diseases (Table 2) . 6, 7 
Clinicopathological Examination
To identify the risk factors associated with LNM of ESCC, several clinicopathological parameters were assessed, including the patient's sex, age, location of the tumor, pathological type, T stage, length of tumor, and histologic differentiation of the tumor. All resected specimens and resected lymph nodes were fixed in 10% formalin and paraffin. These paraffin specimens were sectioned and stained by hematoxylin and eosin. All histopathologic examinations were performed independently and blindly by two pathologists, and 
Statistical Analysis
The relationship between the clinicopathological factors and the LNM was evaluated using the χ 2 test. For multivariate analysis, the forward step-wise procedure was performed using a binary logistic regression model, containing all statistically significant variables in univariate analysis. p Value of less than 0.05 was considered statistically significant. SPSS 18.0 software package was used (SPSS, Chicago, IL).
The sites with LNM rate higher than 15%, an empirical cutoff value, were considered as high-risk areas and were included in CTV of thoracic ESCC patients for radiotherapy.
RESULTS
From February 2003 to September 2011, 1893 patients with thoracic ESCC were surgically treated at Shandong Cancer Hospital.
Tumor Locations and LNM
The LNM sites of thoracic esophageal carcinomas are shown in Table 3 and Figure 1 . Table 4 shows the LNM sites of thoracic ESCC. A total of 25,410 nodes were removed from 1893 patients, with a mean of 13.4 nodes per patient. Lymph node metastases were found in 865 of the 1893 patients, the rate of LNM was 45.7% (865 of 1893).
Clinicopathological Factors Associated with LNM and Subgroup Analysis
The length of tumor (p < 0.001), histologic differentiation (p < 0.001), depth of tumor invasion (p = 0.001), pathological type (p = 0.038), and age (p = 0.045) were closely associated with LNM shown by univariate analysis (Table 1 ). Multivariate analysis suggested that age (p = 0.020, odds ratio [OR] = 0.988), depth of tumor invasion (p < 0.001, OR = 1.735), length of tumor (p < 0.001, OR = 1.155), and histologic differentiation (p < 0.001, OR = 1.980) were strongly associated with LNM ( Table 5 ). The results of further subgroup analysis about tumor invasion, length of tumor, and histologic differentiation are shown in Table 6 .
DISCUSSION
The present study indicates that the pattern of LNM in ESCC is associated with the tumor location, depth of tumor invasion, length of tumor, histologic differentiation, and age. These factors should be considered comprehensively when designing the CTV for radiotherapy of ESCC.
In the present study, 1893 patients with thoracic ESCC were treated with esophagectomy and lymphadenectomy. The role of three-field lymph node dissection in esophageal cancer surgery is controversial. 8 Tachibana et al. 9 showed that the survival rate was significantly improved in ESCC patients treated with three-field lymph node dissection compared with twofield lymph node dissection. In contrast, Shim et al. 10 found that there was no survival benefit from the addition of cervical nodal dissection in esophagectomy for ESCC. We suggest that cervical nodal dissection can be omitted in selected cases, especially for patients who have no cervical LNM on preoperative staging workup.
It has been shown that the depth of tumor invasion, 11 length of tumor, 12 and histologic differentiation 13 were associated with the LNM in ESCC. Similarly, our results also suggest the independent prognostic factors for LNM include depth of tumor invasion (p < 0.001, OR = 1.753), length of tumor (p < 0.001, OR = 1.155), and histologic differentiation (p < 0.001, OR = 1.980) ( Table 5 ). We found that age was a significant predictor of LNM (p = 0.020, OR = 0.988), which was inconsistent with our previous study. 14 The age range of patients in this study was 30 to 85 years, and they were arbitrarily divided into three age groups, 40 years and lesser, 41 to 59 years, and 60 years or more. It is interesting to note that the percentage of positive node was higher in the younger groups (≤40 years, 47.3% positive; 41-59 years, 49.1% positive) than in the older group (≥60 years, 43.3% positive) (p < 0.05). Old age is generally regarded a negative prognostic factor for LNM in thoracic ESCC, yet our results show that the younger age group was associated with an increased risk of LNM. However, this finding does not mean that older patients have lower risks of LNM in ESCC than younger ones. Our results highlight the important role of age in LNM in thoracic ESCC. These unfavorable risk factors should be taken into account when the probability of LNM is evaluated for the treatment design of ESCC. The prevalence of lymphatic metastasis varies in esophageal carcinoma of different locations. We speculate that LNM in the upper thoracic esophageal carcinoma tends to appear upward, whereas LNM in the lower thoracic esophageal carcinoma tends to appear downward. In the middle thoracic esophageal carcinoma, LNM could appear both upward and downward, with the latter accounting for a higher proportion. In contrast, in the lower thoracic esophageal carcinoma, the most common LNM site was the abdominal nodes.
Radiation therapy is an important treatment modality for the local control of esophageal carcinoma. 15, 16 Although concurrent chemotherapy and radiotherapy have been used as the standard treatments for advanced esophageal carcinoma, locoregional control rates are still below 50% and the 5-year overall survival rate is only 26%. 17 Esophageal cancer is characterized by the high rate of nodal involvement and its spread pattern is not always predictable. In addition, skip metastases are frequently observed in esophageal cancer. [18] [19] [20] Therefore, it is difficult to define the CTV margin of radiotherapy for esophageal cancer without a clear understanding of the LNM pattern. CTVs include two components, the subclinical invasion and intramural metastasis of primary tumor, and the subclinical lymph node (CTVn). In Radiation Therapy Oncology Group 85-01, 21 the irradiation field was extended from the supraclavicular region downward to the gastroesophageal junction, though the supraclavicular nodes were omitted in patients with tumors in the lower third of the esophagus. In a subsequent study, Radiation Therapy Oncology Group 94-05, 22 a 5-cm margin superior and inferior to and a 2-cm margin lateral to the block edge were used in a typical esophageal cancer protocol. This study mainly focused on the CTVn of ESCC patients. Obviously, CTVn is not to be considered in the CTV delineation. Locoregional recurrence because of missed targets and treatment-related toxicity, caused by large fields of radiation, still occur in a substantial proportion of patients. In summary, that may be the reason that locoregional control rates and the 5-year overall survival rate are low for advanced esophageal carcinoma patients after radiation therapy.
In our study, those sites with LNM rate higher than 15%, an empirical cutoff value, were considered as high-risk areas and were included in the target volume of patients with thoracic ESCC. Tumor invasion into the esophageal submucosa could cause regional LNM. Deeper tumor invasion can lead to more opportunities of tumor cells invading lymphatic vessels and higher rates of LNM. 11, 23 The results of subgroup analysis also suggest that radiation oncologists should design individualized radiotherapeutic CTVn for thoracic ESCC patients with different tumor invasion. For T3-4 upper thoracic ESCC, we suggest that cervical and upper mediastinal nodes should be included in the CTV. The bidirectional transfer probability of middle thoracic esophageal carcinoma is higher. Therefore, more comprehensive coverage of mediastinal lymph nodes should be considered. CTV for T3-4 middle thoracic ESCC should include middle mediastinal and abdominal portions, whereas for T1-2 ESCC, only the middle mediastinal lymph nodes may be delineated as irradiation target volume. With regard to the T3-4 lower thoracic ESCC, the CTV should cover the middle, lower mediastinal, and abdominal regions, whereas for T1-2 ESCC, only the lower mediastinal and abdominal regions should be considered.
In addition, it is important for the radiation oncologist to recognize that tumor length is included in the classification of disease stage. It has been reported that length is associated with LNM rate, suggesting that longitudinal growth in the lymphatic-rich submucosa may be the most important factor resulting in regional LNM. 24 The patients were divided into three groups by their tumor length (greatest dimension): 4 cm or lesser, 4 to 6 cm, and 6 cm or more. For middle thoracic ESCC patients with tumors measuring 4 to 6 cm or 6 cm and more, middle mediastinal and abdominal portions should be Depth, the depth of tumor invasion; Length, the length of tumor; Diff, the histologic differentiation; Path, pathological morphology type; OR, odds ratios; CI, confidence interval. 25 For middle thoracic ESCC patients with poorly differentiated tumors, the middle mediastinal and abdominal portions should be included in the CTV. However, for patients with well-differentiated tumors, only the middle mediastinal should be delineated as irradiation target volume. For lower thoracic ESCC patients with poorly differentiated tumors, the CTV should cover the middle, lower mediastinal and abdominal regions. Whereas for patients with well-differentiated tumors, only the lower mediastinal and abdominal regions should be delineated as irradiation target volume. Because of the limit of the number of patients with upper thoracic ESCC, we cannot draw clear conclusions on different subgroups.
The results of further subgroup analysis suggest that T3-4 thoracic ESCC patients with tumors measuring 4 to 6 cm or 6 cm and more may still have a substantial risk for LNM, especially if histologic differentiation is poor. Therefore, for the large, deeply invasive, longer tumors, and poorly differentiated thoracic ESCC, the irradiation field should be enlarged appropriately. Factors identified as independent prognostic factors for LNM in our analysis were depth of tumor invasion, length of tumor, and histologic differentiation. The incidence of LNM was significantly higher for thoracic ESCC patients with one or more of these independent risk factors. Therefore, we suggest that the irradiation field should be enlarged appropriately for these patients. Nakagawa et al. 26 reported that for each part of thoracic ESCC, the LNM rate of cervical and upper mediastinal lymph nodes is higher. The lower neck and upper mediastinum are rich in lymphatic vessels, nerves, and large blood vessels adjacent to organs. Therefore, it is difficult to perform a complete lymphadenectomy, leading to residual subclinical lesions, LNM, and recurrence of esophageal cancer. 24 Thus, cervical and upper mediastinal lymph nodes theoretically need to be irradiated for all thoracic ESCC. Yet, our results show that LNM rate of cervical and upper mediastinal sites for the lower thoracic esophageal carcinoma were 2.0% and 2.2%, respectively. Although these two sites were once suggested in radiation therapy for lower thoracic esophageal carcinoma, we advocate them free of irradiation for the toxicity and complication of extensive radiotherapy. An irradiation field that is too small may miss the cancerous cells, whereas an overly large field will cause unnecessary radiation damage.
The risk is that larger CTVs carry a higher risk for normal tissue toxicity. How to minimize the damage to the radiosensitive organs close to the tumor is a major challenge for radiation oncologists, especially as concurrent chemoradiotherapy is becoming a standard treatment. The choice of intensity-modulated radiotherapy technique is clearly important. In the treatment of esophageal carcinoma, intensity-modulated radiotherapy may be used either to reduce the dose delivered to normal tissue, or to escalate the dose delivered to esophageal tumors. 27 In conclusion, CTV must be customized by experienced oncologists according to the various clinical factors that influence LNM. Irradiation of the selective regional lymph node and the correlated lymphatic drainage regions should be performed according to the clinical and pathological factors, such as depth of tumor invasion, length of tumor, and the histologic differentiation. For the large, deeply invasive longer tumors and poorly differentiated thoracic ESCC, the irradiation field should be enlarged appropriately.
